Project 1: Microbiology of ME/CFS
项目1:ME/CFS微生物学
基本信息
- 批准号:10246406
- 负责人:
- 金额:$ 75.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-22 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAntibioticsAntibodiesAntiviral AgentsAutoantibodiesB-LymphocytesBacteriaBase SequenceBiological AssayBiological MarkersBloodChronic Fatigue SyndromeCommunitiesDataDiagnosisDiseaseDouble-Stranded RNAFailureHerpesviridaeHigh-Throughput Nucleotide SequencingImmune PlasmaImmune responseImmunityInfectionInfectious AgentInflammationInterventionIntravenous infusion proceduresLaboratoriesLeadMethodsMicrobeMicrobiologyMonoclonal AntibodiesNatural ImmunityNucleic AcidsOralPathogenesisPatient observationPatientsPeptidesPeripheral Blood Mononuclear CellPlasmaPolymerase Chain ReactionPrevalenceProbioticsReportingRestRisk FactorsRoleRunningSamplingSerologyShotgunsSurveysTLR3 geneVertebrate VirusesVirusVirus ReplicationWorkanaloganimal model developmentbacterial communitybacteriomebasecase controlclinical subtypescytokinedensitydetection methoddysbiosisfecal transplantationfungusimmune functioninsightmetabolomicsmetagenomic sequencingmicrobialmycobiomenovelpathogenresponsetranscriptome sequencingvirome
项目摘要
Project 1
Microbiology of ME/CFS
Abstract
Many patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) report a prodrome
consistent with infection and/or inflammation. Up to 40% of patients are reported to respond to intravenous
infusions of the Toll-like receptor 3 agonist, Ampligen, a double-stranded RNA analogue proposed to inhibit
viral replication. Others report responses to antiviral drugs specific for herpesviruses, pre- and probiotics or
fecal transplantation, or monoclonal antibodies that deplete B cells. We hypothesize that at least some
ME/CFS patients have an infectious trigger for their disease, and that failures to implicate infectious agents
reflect inadequate sampling and/or inappropriate assays. To explore the role of infection and immunity in
ME/CFS, we will exploit sensitive sequence-based methods for detection and characterization of bacteria,
viruses, and fungi, using blood, oral, and fecal samples from well characterized ME/CFS cases and controls.
This project has the potential to lead to the development of animal models based on dysbiosis as well as the
identification of patients with ME/CFS who may benefit from antiviral, antibiotic, or probiotic interventions.
项目1
微生物学ME/CFS
摘要
许多肌痛性脑脊髓炎/慢性疲劳综合征(ME/CFS)患者报告前驱症状
与感染和/或炎症一致据报道,高达40%的患者对静脉注射
输注Toll样受体3激动剂Ampligen,一种双链RNA类似物,
病毒复制其他人报告了对疱疹病毒特异性抗病毒药物、益生菌和益生菌的反应,
粪便移植,或消耗B细胞的单克隆抗体。我们假设至少有一些
ME/CFS患者的疾病具有感染性触发因素,并且未能涉及感染因子
反映了采样不充分和/或分析不适当。探讨感染和免疫在
ME/CFS,我们将利用敏感的基于序列的方法来检测和表征细菌,
病毒和真菌,使用血液,口腔和粪便样本充分表征ME/CFS病例和对照。
该项目有可能导致基于生态失调的动物模型的发展,
确定可能从抗病毒、抗生素或益生菌干预中获益的ME/CFS患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
W. Ian Lipkin其他文献
W. Ian Lipkin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('W. Ian Lipkin', 18)}}的其他基金
Highly multiplexed platforms for diagnosis of infection and immunity
用于诊断感染和免疫的高度多重平台
- 批准号:
9241960 - 财政年份:2017
- 资助金额:
$ 75.65万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 75.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 75.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 75.65万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 75.65万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 75.65万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 75.65万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 75.65万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 75.65万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 75.65万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 75.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




